Feature

Abortion debate may affect Rx decisions for pregnant women


 

Chilling effect on prescribing

Some physicians anticipate that drugs such as the “morning-after” pill (levonorgestrel) will become less available as restrictions go into effect, since these are medications designed to prevent pregnancy.*

However, the ongoing effort to put a lid on abortion measures has prompted concerns about a trickle-down effect on other medications that are otherwise life-changing or lifesaving to patients but pose a risk to the fetus.

Several drugs are well documented to affect fetal growth and development of the fetus, ranging from mild, transitory effects to severe, permanent birth defects, said Ronald G. Grifka, MD, chief medical officer of University of Michigan Health-West and clinical professor of pediatrics at the University of Michigan Medical School, Ann Arbor. “As new medications are developed, we will need heightened attention to make sure they are safe for the fetus,” he added.

Dr. Ronald G. Grifka, chief medical officer of University of Michigan Health-West and clinical professor of pediatrics at the University of Michigan Medical School, Ann Arbor

Dr. Ronald G. Grifka

Certain teratogenic medications are associated with a high risk of abortion even though this isn’t their primary use, noted Christina Chambers, PhD, MPH, co-director of the Center for Better Beginnings and associate director with the Altman Clinical & Translational Research Institute at the University of California, San Diego.

Christina Chambers, PhD, MPH, professor of pediatrics, UCSD Christina Chambers

Dr. Christina Chambers

“I don’t think anyone would intentionally take these drugs to induce spontaneous abortion. But if the drugs pose a risk for it, I can see how the laws might be stretched” to include them, said Dr. Chambers.

Methotrexate, a medication for autoimmune disorders, has a high risk of spontaneous abortion. So do acne medications such as isotretinoin.

Patients are usually told they’re not supposed to get pregnant on these drugs because there’s a high risk of pregnancy loss and risk of malformations and potential learning problems in the fetus. But many pregnancies aren’t planned, said Dr. Chambers. “Patients may forget about the side effects or think their birth control will protect them. And the next time they refill the medication, they may not hear about the warnings again.”

With a restrictive abortion law or ban in effect, a woman might think: “I won’t take this drug because if there’s any potential that I might get pregnant, I won’t have the option to abort an at-risk pregnancy.” Women and their doctors, for that matter, don’t want to put themselves in this position, said Dr. Chambers.

Rheumatologist Megan Clowse, MD, who prescribes several medications that potentially cause major birth defects and pregnancy loss, worries about the ramifications of these accumulating bans.

Dr. Megan Clowse, associate professor of medicine at Duke University's division of rheumatology and immunology

Dr. Megan Clowse

“Methotrexate has been a leading drug for us for decades for rheumatoid arthritis. Mycophenolate is a vital drug for lupus,” said Dr. Clowse, associate professor of medicine at Duke University’s division of rheumatology and immunology.

Both methotrexate and mycophenolate pose about a 40% risk of pregnancy loss and significantly increase the risk for birth defects. “I’m definitely concerned that there might be doctors or women who elect not to use those medications in women of reproductive age because of the potential risk for pregnancy and absence of abortion rights,” said Dr. Clowse.

These situations might force women to use contraceptives they don’t want to use, such as hormonal implants or intrauterine devices, she added. Another side effect is that women and their partners may decide to abstain from sex.

Pages

Recommended Reading

Adding rituximab to belimumab offers no help for lupus
MDedge Dermatology
Validity of commercial serologic tests for dermatomyositis still questionable
MDedge Dermatology
A 22-year-old presented with erythematous papules on her fingers and toes
MDedge Dermatology
Rituximab and COVID-19 vaccines: Studies begin to answer key questions
MDedge Dermatology
Lilly calls it quits on baricitinib’s development for lupus
MDedge Dermatology
Real-world data reinforce stem cell transplant for progressive systemic sclerosis
MDedge Dermatology
New ivermectin, HCQ scripts highest in GOP-dominated counties
MDedge Dermatology
COVID-19 infection linked to risk of cutaneous autoimmune and vascular diseases
MDedge Dermatology
Lupus may lead to worse stroke outcomes for women, but not men
MDedge Dermatology
Myositis guidelines aim to standardize adult and pediatric care
MDedge Dermatology